Researchers have developed a potential blood test that could detect chronic traumatic encephalopathy (CTE) in living individuals, a significant advancement as the disease can currently only be confirmed posthumously. This development is being hailed as a "game changer" by experts, potentially paving the way for earlier intervention for those affected by the degenerative brain disease.

Recent studies indicate that up to 25% of National Football League (NFL) players may develop CTE, a condition linked to repeated head injuries that can manifest in personality changes, cognitive decline, addiction, psychosis, and an increased risk of ALS. Previously, definitive diagnosis required post-mortem examination of brain tissue.

A study led by Boston University and Banner Health involved 21 former American football players. Blood samples were collected while the participants were alive, and their brains were later donated for examination after death. The study found that 18 participants (85%) had CTE, with 16 of those exhibiting stage 3 or 4 CTE. While CTE can affect individuals from their early 20s, it is more commonly found in older individuals.

Identifying CTE Biomarkers

High-stage CTE is associated with the buildup of a protein called p-tau in the brain, which disrupts cell function and leads to neurodegeneration. This protein buildup is also present in other neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The researchers hypothesized that increased p-tau in the brain would correlate with higher levels of a specific biomarker in the blood: endogenously cleaved microtubule-binding region tau (eMTBR-tau).

This biomarker is already used in Alzheimer's diagnosis. The study's findings suggest that eMTBR-tau levels were significantly elevated in individuals with higher stages of CTE but not in those with low-stage CTE or no CTE. Participants who had both CTE and Alzheimer's showed the highest levels of eMTBR-tau.

Future Implications for CTE Diagnosis and Treatment

Symptoms of CTE can include memory loss, confusion, impaired decision-making, irritability, aggression, and depression, as well as movement issues. Currently, medical professionals can only rule out other conditions, as there is no definitive diagnostic tool for living patients.

While the current study is in its early stages with a small sample size, "if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment," stated Michael Alosco, co-director of clinical research at the Boston University CTE Center. Further research will require larger cohorts and varied stages of CTE and co-occurring conditions.

There is no cure for CTE, and the condition progresses over time. However, treatments can help manage symptoms, including cognitive therapy, behavioral therapy, and medication for issues like depression and sleep disturbances. The development of a reliable blood test could be as revolutionary for CTE diagnosis and treatment as it has been for Alzheimer's disease, according to Nicholas Ashton, another author of the study.